Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). $50.0 million common-stock offering: 47,619,048 shares at $1.05 per share.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50.0 million common-stock offering: 47,619,048 shares at $1.05 per share
- Expected net proceeds of $46.80 million after underwriting discounts and offering expenses
- 30-day underwriter option for 7,142,857 additional shares, potentially raising net proceeds to $53.85 million
- Potential shareholder dilution from up to 54,761,905 newly issued shares
- Closing expected June 12, 2026, subject to customary conditions
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only Regulation FD filing-status language
- No substantive business, financial, or operational disclosure for investors to evaluate
Item EX-99.1 · Exhibit EX-99.2
- Proposed underwritten public offering of common stock; size, pricing and completion remain subject to market conditions
- Underwriters may purchase up to 15% additional shares through a 30-day option, creating potential further dilution
- Proceeds targeted for Symvess commercialization, hemodialysis BLA supplement filing, pipeline development and working capital
- Equity raise supports growth initiatives but signals near-term reliance on external capital financing
- Symvess is FDA-approved only for extremity vascular trauma; hemodialysis use remains investigational pending regulatory action
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.